Lupin announced that its subsidiary, Lupin Pharmaceuticals (collectively, Lupin) has launched its Fenofibrate tablets, 48 mg and 145 mg strengths in the US. Lupin had earlier received final approval for the same from the US Food and Drug Administration (FDA).
Lupin’s Fenofibrate tablets are the AB rated generic equivalent of Abbott’s Tricor tablets and are indicated for Primary Hypercholesterolemia or Mixed Dyslipidemia and Severe Hypertriglyceridemia. Abbott’s Tricor tablets, 48 mg and 145 mg had sales of $1.26 billion as per IMS Health, June, 2012.
Commenting on the approval, Vinita Gupta, CEO, Lupin Pharmaceuticals and Group President, Lupin said, “We are happy to bring this product to market in the US. Patients can be assured that they are receiving the same high quality product they have been accustomed to at a more affordable price.”
EP News Bureau
- Advertisement -
